Blog · Safety · Published 2026-08-09
How to Report a Compounded GLP-1 Problem to FDA MedWatch — and Why It Matters
If a compounded GLP-1 product harms you, arrives wrong, or behaves unexpectedly, the report goes to FDA MedWatch — the voluntary reporting system behind statistics like the 730+ adverse-event reports FDA has logged for compounded tirzepatide. Reportable events include suspected reactions and side effects requiring care, dosing errors (including ones caused by concentration or labeling confusion), product-quality problems (particulates, discoloration, broken sterility indicators), and suspected counterfeit product. You don't need certainty that the product caused the problem — MedWatch collects signals, and adjudication is FDA's job, not yours. Reporting takes about ten minutes online and can be done by patients directly, alongside (not instead of) telling your prescriber and the pharmacy.
What to gather before you file
Five things make a report useful: the product details from the vial label — pharmacy name, drug, concentration in mg/mL, lot or prescription number, beyond-use date; the program you purchased through; what happened and when, in dates; what care was needed, if any; and photos of the label and product. This is the same documentation discipline our warm-shipment and vial-math guides teach, pointed at a second audience. File at FDA's MedWatch portal (Form 3500 for consumers); the pharmacy should also receive your complaint directly — complaint files are part of the records an inspection examines, which is exactly how individual reports become systemic visibility.
Why bother, given the numbers are 'raw'
Adverse-event counts are unadjudicated and denominatorless — this site says so every time it cites them — but raw is not useless: reporting patterns are how FDA prioritized compounded-GLP-1 dosing errors, how salt-form concerns surfaced, and part of how enforcement attention gets allocated. Under-reporting is the known weakness of every voluntary system, which makes each filed report disproportionately valuable. The civic version of this site's whole premise applies: markets with better information fail less. You benefit from the 730 reports other people filed; the ten minutes is how the next reader benefits from yours.
Frequently asked questions
What GLP-1 problems should be reported to MedWatch?
Suspected adverse reactions, dosing errors (including concentration-confusion errors), product-quality defects, and suspected counterfeits — certainty about causation is not required; MedWatch collects signals.
Can patients file MedWatch reports themselves?
Yes — consumers file directly via FDA's online Form 3500 in about ten minutes. Report to your prescriber and the dispensing pharmacy as well; those routes are complementary, not alternatives.
Do adverse-event reports prove compounded GLP-1s are dangerous?
No — counts are raw, unadjudicated, and lack denominators, which this site notes whenever citing them. They are signals that direct regulatory attention, and reporting is what makes the signal exist.
Primary sources
FDA MedWatch; FDA — concerns with unapproved GLP-1 drugs.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.